Chemotherapy and Radiotherapy to Treat Patients With Limited Stage of Small Cell Lung Cancer (SCLC)

• Status: Terminated
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multicenter, phase II, open-label trial to evaluate the efficacy of pemetrexed + carboplatin combined with thoracic radiotherapy in patients with Limited Stage of small cell lung cancer

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Carboplatin; Pemetrexed

Criteria

Inclusion Criteria:

• Histologic and/or cytologic diagnosis of Limited Stage of small cell lung cancer

• Measurable disease

• Good performance status

• Adequate bone marrow reserve, hepatic, pulmonary and renal functions

Exclusion Criteria:

• Serious concomitant systemic disorder

• Prior chemotherapy for this cancer and/or prior thoracic radiotherapy

• Pregnancy/breast-feeding

• Significant weight loss over the previous 6 weeks before study entry

• Inability or unwillingness to take vitamin supplementation and corticosteroids